67 assets in Colorectal Adenocarcinoma

Therapeutic assets addressing Colorectal Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabotamig Colorectal Adenocarcinoma	Arbele Pty Ltd	P1	CC (42)
Bet Bromodomain Inhibitor Zen-3694 Colorectal Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
Emavusertib Colorectal Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)
Fulvestrant Colorectal Adenocarcinoma	Pfizer	P1	CC (41)
Imiquimod Colorectal Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (41)
pf-08032562 Colorectal Adenocarcinoma	Pfizer	P1	CC (41)
Talazoparib Colorectal Adenocarcinoma	Roswell Park Cancer Institute	P1	CC (41)
Sotigalimab Colorectal Adenocarcinoma	M.D. Anderson Cancer Center	P1	CC (40)
[225Ac]Ac-AKY-1189 Colorectal Adenocarcinoma	Aktis Oncology, Inc.	P1	C (39)
[64Cu]Cu-AKY-1189 Colorectal Adenocarcinoma	Aktis Oncology, Inc.	P1	C (39)
Acm-Cpg Colorectal Adenocarcinoma	Brown University	P1	C (39)
Clsp-1025 Colorectal Adenocarcinoma	Clasp Therapeutics, Inc.	P1	C (39)
Efineptakin Alfa Colorectal Adenocarcinoma	National Cancer Institute (NCI)	P1	C (39)
Fluoxetine Colorectal Adenocarcinoma	Jonsson Comprehensive Cancer Center	P1	C (39)
Ozekibart Colorectal Adenocarcinoma	Inhibrx Biosciences, Inc	P1	C (39)
Colobox Colorectal Adenocarcinoma	Clinique Paris-Bercy	N/A	D (30)
Bay 3771249 Colorectal Adenocarcinoma	Bayer	P1	NR ()

Showing 51 to 67 of 67 assets

PreviousPage 2 of 2Next